Legend Biotech Corporation (LEGN)

Legend Biotech Corporation (LEGN) is a global, clinical-stage biopharmaceutical company at the forefront of cell therapy, specializing in chimeric antigen receptor (CAR) T-cell treatments for cancer. Led by CEO Ying Huang, Legend’s mission is to "bring innovative cell therapies to patients worldwide, aiming to cure life-threatening diseases." The company’s flagship product, CARVYKTI (cilta-cel), developed in partnership with Johnson & Johnson, has redefined the treatment landscape for relapsed or refractory multiple myeloma. By late 2025, LEGN stock is viewed as a "Commercial Powerhouse" in transition, as the company scales manufacturing to meet surging global demand. Its vision is to expand its proprietary CAR-T platform into solid tumors and infectious diseases, leveraging its "Global Manufacturing Footprint" with major facilities in New Jersey, Belgium, and China.

The business operations of Legend Biotech are primarily driven by the rapid commercial uptake of CARVYKTI, which saw net trade sales grow 84% year-over-year to $524 million in Q3 2025. The company’s core strategy for 2026, titled "10K & Beyond," focuses on expanding manufacturing capacity to 10,000 annual doses by year-end, with a path to double that capacity by 2028. In fiscal 2025, Legend reported total revenue of approximately $272 million for the third quarter, with a strategic goal of reaching company-wide profitability by 2026. The 2026 roadmap includes moving CARVYKTI into earlier lines of treatment (front-line multiple myeloma), which could triple the addressable patient population. By maintaining a "Clinical Moat"—supported by superior efficacy data compared to competitors—Legend attracts high-tier institutional backing and maintains a cash position of nearly $1 billion as of late 2025. This "Efficacy Edge" is the primary driver for the LEGN stock price, as the company transitions from a R&D-heavy biotech to a profitable, vertically integrated oncology leader.

The LEGN stock is listed on the NASDAQ Global Select Market under the ticker symbol LEGN. As a critical partner in the J&J oncology portfolio, Legend Biotech Inc is a staple for biotech investors focused on the next generation of curative therapies. For investors tracking the LEGN stock price, the key metrics are "Total Patient Reach" and the successful scale-up of the Obelisc manufacturing facility in Ghent. The Legend Biotech stock represents a high-conviction play on the institutionalization of cell therapy as a standard of care.